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Summary The integration of targeted agents to standard
cytotoxic regimens has improved outcomes for patients with
colorectal cancer (CRC) over recent years; however this ma-
lignancy remains the second leading cause of cancer mortality
in industrialized countries. Small molecule inhibitors of heat
shock protein 90 (HSP90) are one of the most actively pursued
classes of compounds for the development of new cancer
therapies. Here we evaluated the activity of ganetespib, a
second-generation HSP90 inhibitor, in models of CRC.
Ganetespib reduced cell viability in a panel of CRC cell lines
in vitro with low nanomolar potency. Mechanistically, drug
treatment exerted concomitant effects on multiple oncogenic
signaling pathways, cell cycle regulation, and DNA damage
repair capacity to promote apoptosis. Combinations of
ganetespib and low-dose ionizing radiation enhanced the ra-
diosensitivity of HCT 116 cells and resulted in superior cyto-
toxic activity over either treatment alone. In vivo, the single-
agent activity of ganetespib was relatively modest, suppress-
ing HCT 116 xenograft tumor growth by approximately half.
However, ganetespib significantly potentiated the antitumor
efficacy of the 5-Fluorouracil (5-FU) prodrug capecitabine in
HCT 116 xenografts, causing tumor regressions in a model
that is intrinsically resistant to fluoropyrimidine therapy. This
demonstration of combinatorial benefit afforded by an HSP90
inhibitor to a standard CRC adjuvant regimen provides an
attractive new framework for the potential application of
ganetespib as an investigational agent in this disease.
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Introduction
In spite of welcome declines in the mortality rate over the past
two decades, colorectal cancer (CRC) remains the second
leading cause of cancer death among adults living in industri-
alized countries. In fact, 2013 estimates predict for more than
140,000 new cases and 50,000 deaths due to this disease in the
United States alone [1]. Advances in, and greater use of,
available screening techniques have resulted in earlier diag-
noses with subsequent medical intervention and thus represent
major contributing factors for the observed decrease in CRC-
related mortality [2]. Further, the introduction of newer che-
motherapeutic drugs and treatment regimens, including those
that incorporate targeted agents, have led to meaningful im-
provements in the median overall survival time for patients
with metastatic CRC [3]. Despite this progress however, the
prognosis for individuals with unresectable advanced disease
continues to be grave and there still exists a substantial unmet
need for novel therapeutic approaches to improve clinical
outcomes in this malignancy.
The molecular chaperone heat shock protein 90 (HSP90)
regulates the maturation and functional stability of an exten-
sive array of cellular target substrates, termed “client” proteins
[4]. Beyond an essential role in maintaining normal tissue
homeostasis, the chaperoning activity of HSP90 is now rec-
ognized as critical for the function of many of these same
clients, as well as mutated and aberrantly expressed forms,
which contribute to nearly every aspect of the tumorigenic
process including immortality, survival, metabolism, angio-
genic, and/or metastatic potential [5, 6]. Inhibiting HSP90
activity triggers the ubiquitination and proteasomal degrada-
tion of its client proteins, in turn providing a highly effective
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means to simultaneously disrupt multiple oncogenic signaling
cascades through a singular molecular target [7, 8]. This
unique characteristic distinguishes this therapeutic strategy
from more traditional targeted approaches, such as kinase
inhibition, that selectively ablate only one or a few
oncoproteins. Pharmacological blockade of HSP90 has there-
fore emerged as an innovative and multifaceted approach for
the development of new antineoplastic agents for a variety of
human cancers [9, 10].
Ganetespib is an investigational small molecule inhibitor of
HSP90 with favorable pharmacologic properties that distin-
guish the compound from other first- and second-generation
HSP90 inhibitors in terms of potency, safety, and tolerability
[11, 12]. Ganetespib has been shown to possess robust anti-
tumor activity against a variety of cancer types in preclinical
studies, including lung, breast, and prostate [13–18].
Moreover, the early clinical evaluation of ganetespib has
revealed encouraging signs of single-agent therapeutic activ-
ity in human tumors. Most notably these have been observed
in a molecularly defined subset of non-small cell lung cancers
oncogenically dependent on EML4-ALK gene rearrange-
ments [19], the fusion protein products of which are highly
sensitive to ganetespib exposure [20]. Interestingly, as part of
the initial Phase I study of ganetespib in patients with solid
malignancies, the most significant demonstration of clinical
efficacy involved a patient with metastatic CRCwho achieved
a partial response (PR) while on-therapy [21]. This provoca-
tive finding therefore prompted a more comprehensive evalu-
ation of ganetespib activity in this malignancy. The results of
the present study suggest that ganetespib may hold consider-
able promise, particularly as part of combinatorial-based strat-
egies, for the treatment of advanced CRC.
Materials and methods
Cell lines, antibodies, and reagents
All colorectal cell lines with the exception of COLO-678 were
obtained from the American Type Culture Collection (ATCC,
Manassas, VA, USA) and maintained at 37 °C in 5 % (v/v)
CO2 using culture medium recommended by the supplier.
COLO-678 cells were obtained from DSMZ (German
Collection of Microorganisms and Cell Cultures,
Braunschweig, Germany). All primary antibodies were pur-
chased from Cell Signaling Technology (CST, Beverly, MA,
USA) with the exception of the GAPDH antibody (Santa Cruz
Biotechnology Inc., Santa Cruz, CA). Ganetespib [3-(2,4-
dihydroxy-5-isopropylphenyl)-4-(1-methyl-1H-1,2,4-triazol-
5(4H)-1] was synthesized by Synta Pharmaceuticals Corp. 5-
Fluorouracil and capecitabine were purchased from Sigma-
Aldrich (St. Louis, MO, USA) and bevacizumab was obtained
from the Dana Farber Cancer Institute (Boston, MA, USA).
Cell viability assays
Cellular viability was assessed using the CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Madison, WI,
USA) according to the manufacturer’s protocol. Colorectal
cancer cell lines were seeded into 96-well plates based on
optimal growth rates determined empirically for each line.
Twenty-four hours after plating, cells were dosed with graded
concentrations of drug for 72 h. CellTiter-Glo was added
(50 %v/v) to the cells, and the plates incubated for 10 min
prior to luminescent detection in a Victor 2 microplate reader
(Perkin Elmer,Waltham,MA, USA). Data were normalized to
percent of control and IC50 values were determined using
XLFit software.
Flow cytometry
For cell cycle analysis, HCT 116 cells were seeded overnight
in a 6-well plate and then exposed to increasing concentrations
of ganetespib (10–1,000 nM) or vehicle (DMSO) for 18 h.
Cells were harvested and stained with propidium iodide using
the BD Cycle TEST PLUS Reagent Kit (BD Biosciences, San
Jose, CA, USA) according to the manufacturer’s instructions.
Twenty thousand cells were analyzed for their DNA content
using a FACS Caliber cytometer (BD Biosciences, Billerica,
MA, USA). For the apoptosis assay, cells were treated over the
same range of ganetespib concentrations for 24 h. Following
treatment, cells were harvested and stained using a
fluorescein-conjugated anti-Annexin V antibody (BD
Biosciences) and apoptosis assessed by flow cytometry.
Western blotting
Following in vitro assays, tumor cells were disrupted in lysis
buffer (CST) on ice for 10 min. Lysates were clarified by
centrifugation and equal amounts of proteins resolved by
SDS-PAGE before transfer to nitrocellulose membranes
(Bio-Rad, Hercules, CA, USA). Membranes were blocked
with Starting Block T20 blocking buffer (Thermo Scientific,
Cambridge,MA, USA) and immunoblotted with the indicated
antibodies. Antibody-antigen complexes were visualized
using an Odyssey system (LI-COR, Lincoln, NE, USA).
Combination drug and irradiation treatment
Exponentially growing HCT 116 cell cultures were treated
with increasing concentrations of ganetespib either alone or
concurrent with exposure to ionizing radiation. Irradiation was
performed at room temperature using a Cesium 137 Mark I
Irradiator (JL Shepherd and Associates, San Fernando, CA,
USA) to a final dose of 2 Gy. Cells were similarly treated in
parallel with DMSO as vehicle controls. At 48 h post-
irradiation, cells were harvested and subject to Annexin V
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Results
Inhibition of oncogenic signaling pathways by ganetespib
induces cell death and suppresses tumor growth in colon
cancer models
Initially, the cytotoxic activity of ganetespib was evaluated
using a panel of 15 CRC lines, where it reduced cell viability
with low nanomolar potency (Table 1). Of interest, the two
most sensitive lines, RKO and LS-411 N, both harbor an
activating BRAFV600E mutation and we have recently report-
ed that expression of this oncogenic driver and established
HSP90 client confers sensitivity to ganetespib in BRAFV600E-
driven melanoma cell lines [22]. One additional line in the
panel, COLO-205, bears the same BRAF mutation and these
cells were also highly sensitive to ganetespib exposure (IC50,
14 nM). Subsequently we investigated the effects of
ganetespib exposure using the well-characterized HCT 116
cell line as our model system. Ganetespib potently reduced
viability in HCT 116 cells with an IC50 value of 14 nM
(Table 1, Fig. 1a). By comparison, the cells were largely
insensitive to the cytotoxic effects of the standard-of-care
chemotherapeutic 5-Fluorouracil (5-FU), which had an IC50
value of approximately 10 μM (Fig. 1a).
Next we examined expression changes in HSP90 client
proteins and signaling pathways associated with colon cancer
progression. As shown in Fig. 1b, ganetespib treatment result-
ed in a dose-dependent destabilization of MET receptor tyro-
sine kinase expression in HCT 116 cells and this was accom-
panied by inactivation of one of its downstream effector
pathways, as evidenced by the loss of phosphorylated Src
activity. Ganetespib exposure also promoted the dose-
dependent degradation of EGFR and IGF-1R receptors, loss
of AKT signaling activity (shown by reductions in both total
and phosphorylated AKT protein levels), and decreased ex-
pression of phosphorylated 4E-BP1, indicative of disruption
of the mTOR (mammalian target of rapamycin) pathway
(Fig. 1c). Loss of ERK activity followed a similar dose-
dependence, indicating that ganetespib treatment was exerting
direct effects on the MAPK pathway. Taken together, such
coordinate impacts on multiple signaling cascades due to
targeted HSP90 inhibition underscore the potent cytotoxic
activity of ganetespib in this colon cancer cell line.
To examine whether these in vitro effects on viability and
cellular signaling translated to antitumor activity in vivo, we
evaluated the efficacy of single-agent ganetespib treatment on
the growth of HCT 116 xenografts. The highest non-severely
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analysis by flow cytometry. HCT 116 cells treated with graded
concentrations of ganetespib with or without simultaneous
ionizing radiation were additionally harvested at 24 h and
protein expression changes evaluated by Western blot. For
microscopic studies, cells were treated with 100 nM
ganetespib or 2 Gy irradiation, either alone or in combination,
for 48 h. Cells were washed, fixed, and permeabilized before
staining with Alexa Fluor® 594 phalloidin (Life
Technologies, Grand Island, NY, USA) for 30 min. Slides
were mounted using DAPI-containing mounting medium
(VECTASHIELD, Vector Labs, Burlingame, CA, USA) and
images obtained using an EVOS-FL fluorescent microscope
(Life Technologies).
In vivo xenograft models
CD-1 nude mice (Charles River Laboratories, Wilmington,
MA) at 7–12 weeks of age were maintained in a pathogen-free
environment and all in vivo procedures were approved by the
Synta Pharmaceuticals Corp. Institutional Animal Care and
Use Committee. HCT 116 (5×106) cells were subcutaneously
implanted into female mice and animals bearing established
tumors (~150mm3) were randomized into treatment groups of
8. For evaluating single-agent activity, mice were dosed with
vehicle or 150 mg/kg ganetespib (i.v.) formulated in DRD
(10 % DMSO, 18 % Cremophor RH 40, 3.6% dextrose) on a
weekly schedule. For the combination experiment, animals
were treated over a 3 week cycle as follows: i.v. ganetespib
(150 mg/kg) once a week, p.o. capecitabine (400 mg/kg) daily
for the first 14 days, or both regimens in combination. Tumor
volumes (V) were calculated by caliper measurements of the
width (W), length (L) and thickness (T) of each tumor using
the formula: V=0.5236(LWT). Tumor growth inhibition was
determined from the change in average tumor volumes of each
treated group relative to the vehicle-treated, or itself in the case
of tumor regression. Statistical significance was determined
using two-way ANOVA followed by Bonferroni post tests.
toxic dose of ganetespib on a weekly dosing regimen has
previously been determined to be 150 mg/kg [11]. As shown
in Fig. 1d, tumor volumes in mice bearing HCT 116 xeno-
grafts that were treated on this regimen were decreased by
approximately half compared to those of control animals (T/C
value 52%). In addition, the schedule was well tolerated, with
no toxicity or significant changes in body weight observed
over the 3-week period (data not shown).
Modulation of cell cycle protein expression by ganetespib
induces growth arrest and apoptosis
We have previously shown for other tumor types that, in
addition to oncogenic signaling pathways, profound effects
on cell cycle regulatory proteins contribute to the antitumor
activity of ganetespib [13, 18]. Cell cycle analysis revealed
that ganetespib exposure led to a dose-dependent G1 accumu-
lation of HCT 116 cells, which was associated with a con-
comitant loss of S phase (Fig. 2a). At the molecular level,
observed elevations in the levels of two protein markers
expressed predominantly in the G1 phase, p21 and p27, were
consistent with this cellular response (Fig. 2b). Interestingly,
differential effects were seen on the expression of CHK1 and
CHK2, two functionally overlapping serine/threonine kinases
that play critical roles within the cell cycle as genome integrity
checkpoints. While ganetespib treatment caused a potent re-
duction in CHK1 protein expression, this contrasted with an
upregulation of CHK2, which becomes activated primarily
within the context of DNA damage (Fig. 2b). In addition,
activation of CHK2 requires phosphorylative events and the
higher molecular weight form of the protein observed follow-
ing ganetespib exposure is consistent with induced expression
of the kinase in an active state (arrow). This was confirmed by
loss of the higher molecular weight CHK2 following phos-
phatase treatment (Supplementary Fig. S1).
More extensive characterization of the impact of
ganetespib on genomic integrity revealed that drug treatment
of HCT 116 cells promoted degradation of the DNA damage-
repair protein RAD51 and induced elevations in the phosphor-
ylated form of histone H2AX, a sensitive indicator of DNA
Fig. 1 Ganetespib activity in HCT 116 colon cancer cells in vitro and
in vivo. a HCT 116 cells were treated with increasing concentrations of
ganetespib or 5-FU and cell viability assessed after 72 h. bHCT 116 cells
were exposed to graded concentrations of ganetespib or vehicle (V) for
24 h as indicated. Cell lysates were immunoblotted using antibodies
against MET and phosphorylated Src (p-Src) as shown. GAPDH was
included as a loading control. cHCT 116 cells were exposed to vehicle or
ganetespib (25, 50 and 100 nM) for 24 h as indicated. Cell lysates were
immunoblotted using antibodies against EGFR, IGF-1R, phosphorylated
ERK (p-ERK), total ERK, phosphorylated AKT (p-AKT), total AKT, and
phosphorylated 4E-BP1 (p-4E-BP1). d Mice bearing established HCT-
116 xenografts (n=8/group) were i.v. dosed with 150 mg/kg ganetespib
once weekly over a 3 week cycle. % T/C values are indicated to the right
of each growth curve and the error bars are the SEM; (*, p<0.05)
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double-strand break formation (Fig. 2c). This was accompa-
nied by reductions in the levels of the anti-apoptotic regulator
Bcl-XL as well as a concomitant and robust increase in
expression of the death domain serine/threonine kinase RIP
(Fig. 2c). Taken together, this correlative loss of a pro-survival
modulator with increased pro-apoptotic protein expression
suggested that perturbation of the cell cycle and DNA repair
pathways following ganetespib treatment ultimately triggered
apoptosis. This premise was further supported by Annexin V
staining data showing that HCT 116 cells treated with esca-
lating doses of ganetespib for 24 h exhibited a dose-dependent
increase in the percentage of apoptotic cells (Fig. 2d).
Ganetespib treatment increases the radiosensitivity of HCT
116 cells in vitro
Inhibition of HSP90 may enhance the sensitivity of tumor
cells to the effects of ionizing radiation (IR). Therefore we
investigated the in vitro radiosensitizing activity of ganetespib
using the HCT 116 colon cancer model. Cells were treated
with ganetespib either alone or in combination with a low,
constant IR dose of 2 Gy. This dose level was selected since,
in the absence of drug, it did not elicit any degree of apoptotic
cell death at 48 h (Fig. 3a). As expected, cellular exposure to
ganetespib alone resulted in a modest, dose-dependent in-
crease in the percentages of Annexin V-positive cells by this
time point. However, the degree of apoptotic induction was
several fold higher in cells that underwent combined
ganetespib-IR treatment (Fig. 3a). Thus, the addition of
ganetespib to low dose radiation dramatically potentiated the
cytotoxic effects of irradiation and to levels above those seen
for drug addition alone (Fig. 3a).
Molecular changes that resulted from this cooperative en-
hancement of radiosensitivity were subsequently analyzed by
Western blot (Fig. 3b). CHK1 is an important regulator of G2
arrest and abrogation of the G2/M checkpoint can sensitize
cancer cells to IR [23]. In agreement with the data presented in
Fig. 2b, CHK1 protein expression was potently destabilized
following ganetespib treatment. Notably, this response was
amplified in HCT 116 cells exposed to the combination of
ganetespib plus IR. CHK2 activation was similarly augmented
in combination treated cells, suggesting an enhanced reactive
Fig. 2 Ganetespib modulates cell cycle expression and induces growth
arrest and apoptosis in HCT 116 colon cancer cells. aHCT 116 cells were
treated with increasing concentrations of ganetespib as indicated. Cell
cycle distribution was determined by flow cytometry 18 h post-treatment.
b HCT 116 cells were treated with graded concentrations of ganetespib
for 18 h. Cell lysates were immunoblotted using antibodies against
CHK1, CHK2, p21 and p27. Arrow depicts higher molecular weight
form of CHK2 induced following ganetespib treatment. c HCT 116 cells
were exposed to increasing concentrations of ganetespib for 24 h. Cell
lysates were immunoblotted using antibodies against RAD51, phosphor-
ylated histone H2AX (p-histone H2AX), Bcl-XL and RIP, as indicated. d
Quantification of apoptosis as assessed by Annexin V positivity. HCT
116 cells were exposed to increasing concentrations of ganetespib for
24 h and Annexin V/PI staining measured by flow cytometry
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response to genotoxic stress. Consistent with this, the levels of
the DNA damage repair protein RAD51 were effectively
suppressed in a drug dose-dependent manner in ganetespib-
IR treated cells, and overall levels of p-histone H2AX were
increased by combination treatment. Taken together, these
data suggest that the diminished capacity for DNA repair
conferred by ganetespib may contribute to a higher degree
of DNA double strand formation arising from IR exposure. As
predicted by the analysis shown in Fig. 3a, levels of cleaved
caspase 7 and cleaved PARP, both markers of apoptotic in-
duction, showed higher relative expression in ganetespib-IR
treated cells.
These findings were further supported by microscopic
examination of HCT 116 cells (Fig. 3c). Irradiation with
2 Gy alone had no effect on nuclear morphology at 48 h, in
contrast to the widespread distribution of condensed,
Fig. 3 Ganetespib sensitizes HCT 116 colon cancer cells to ionizing
radiation. a HCT 116 cells were treated with increasing doses of
ganetespib either alone or in combination with 2 Gy dosing of irradiation
(Ganetespib+2 Gy). At 48 h post-IR, quantification of apoptosis was
assessed by Annexin V-positivity measured by flow cytometry. b HCT
116 cells were treated with increasing doses of ganetespib (0, 25, 50 and
100 nM), either alone or in combination with 2 Gy irradiation. At 24 h
post-treatment, lysates were prepared and immunoblotted using
antibodies against CHK1, CHK2, RAD51, phosphorylated histone
H2AX (p-histone H2AX), cleaved Caspase 7, and cleaved PARP.
GAPDH was included as a loading control. c Representative images of
HCT 116 cells treated with vehicle, 100 nM ganetespib, irradiated with a
single dose of 2 Gy or simultaneously treated with the combination for
48 h, as indicated. Immunofluorescence was performed on cells stained
for actin (red) and DAPI (blue). Arrowheads depict examples of large,
multinucleated cells. Original magnification, 20×
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fragmented nuclei characteristic of apoptotic cell death fol-
lowing 100 nM ganetespib exposure. The ganetespib-IR com-
bination resulted in fewer viable cells at this time point, with a
high percentage of those remaining showing signs of mitotic
catastrophe, as evidenced by enlarged micro- and multinucle-
ated cells, in addition to extensive nuclear condensation
(Fig. 3c). Taken together, these data show that simultaneous
ganetespib treatment and irradiat ion can induce
radiosensitization and promote cell death in CRC tumor cells.
Ganetespib potentiates the antitumor efficacy
of fluoropyrimidine-based chemotherapy in CRC xenografts
As presented in Fig. 1, ganetespib displayed modest single-
agent efficacy in HCT 116 xenografts in vivo. Further, it has
been proposed that HSP90 inhibitors, as a class, will likely be
most effective in the clinical setting as part of rationally
designed combination therapies [24]. In clinical practice, bo-
lus 5-FU plus leucovorin (5-FU/LV) therapy is the standard
adjuvant treatment for colon cancer. Capecitabine, an oral
fluoropyrimidine and prodrug of 5-FU, has more recently
become an established alternative to 5-FU/LV as first-line
treatment for metastatic CRC.We therefore examinedwhether
the addition of ganetespib to capecitabine would improve
therapeutic indices in the HCT 116 xenograft model. As
shown in Fig. 4, weekly administration of ganetespib
(150 mg/kg) over a 3 week schedule resulted in 48 % tumor
growth inhibition (T/C value, 52 %). Mice bearing HCT 116
tumors were also administered capecitabine p.o. (400 mg/kg)
daily for the first 14 days on-study, and then dosing was
suspended for the final 7 days (simulating the clinical dosing
schedule). This regimen resulted in a similar degree of tumor
growth suppression (T/C value, 44 %; Fig. 4a). Strikingly,
concurrent treatment with both drugs at the same dose levels
and schedule resulted in a significant improvement in antitu-
mor activity, inducing 52 % tumor regression (p<0.05 vs.
capecitabine treatment alone). This finding clearly demon-
strated that co-treatment with ganetespib robustly potentiated
the activity of capecitabine in this model. In addition, the
combination was well tolerated, with no significant loss of
body weight seen after 3 weeks of dosing (data not shown).
Discussion
The clinical management of CRC is typically dictated by the
stage of the disease. Patients who present with early stage,
localized tumors are amenable to curative resection surgery.
Adjuvant chemotherapy is indicated for patients with Stage III
disease or higher, since this modality is superior to surgical
intervention alone in terms of improving disease-free and
overall survival as well as preventing recurrence [25].
Chemotherapeutic regimens include the traditional cytotoxic
drugs 5-FU, capecitabine, irinotecan, and oxaliplatin, with
newer biologic agents bevacizumab, cetuximab, and
panitumumab now being employed in combinatorial ap-
proaches for metastatic CRC [26]. Indeed, the addition of
molecularly targeted agents to existing chemotherapeutic reg-
imens has effectively doubled the survival outlook for patients
with metastatic disease over the past decade [3, 26]. This
approach thus serves as an encouraging paradigm for the
design of novel strategies to provide continued improvements
for patients with advanced CRC.
Here we investigated the antitumor activity profile of
ganetespib, a second-generation inhibitor of HSP90 currently
under clinical evaluation in multiple human trials. Ganetespib
potently reduced cell viability in vitro in a panel of CRC cell
lines, with drug exposure resulting in the dose-dependent
destabilization of multiple HSP90 client proteins, including
MET, EGFR, IGF-1R and AKT. Overall, the combinatorial
blockade of multiple key signaling components required for
CRC cell growth and survival, perturbation of cell cycle
regulation, and subsequent induction of apoptosis were suffi-
cient to account for the potent cytotoxic activity of this agent.
These findings complement and extend those of a recent study
showing that ganetespib exerts robust antiangiogenic activity
in preclinical models of CRC, through disruption of HIF-1α
and STAT3 signaling [27].
Despite their therapeutic promise, no HSP90 inhibitors are
currently approved for cancer treatment. The most impressive
clinical effects observed with HSP90 inhibitor monotherapy
have arisen in defined subsets of tumors that exhibit a high
degree of oncogenic dependence on particular client proteins
e.g., ALK-driven non-small cell lung cancer and HER2-
amplified breast cancer [24]. The proteins that show the
Fig. 4 Combination ganetespib plus capecitabine treatment confers su-
perior antitumor efficacy in CRC xenografts. Over a 3 week cycle, mice
bearing established HCT 116 xenografts (n=8/group) were i.v. dosed
with 150 mg/kg ganetespib 1×/week or p.o dosed with 400 mg/kg cap-
ecitabine daily for 14 consecutive days, either alone or in combination. %
T/C values are indicated to the right of each growth curve and the error
bars are the SEM. Combination ganetespib+capecitabine treatment re-
sulted in significant tumor regression (*, p<0.05)
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highest frequency of alteration as part of colorectal tumori-
genesis, APC and KRAS, are themselves not HSP90 clients.
Thus, in general, this malignancy might not be expected to be
highly responsive to targeted HSP90 therapeutic intervention.
A possible exception, however, involves the serine/threonine
kinase BRAF, mutant forms of which are highly reliant on the
chaperone function of HSP90 for stability and function [28].
Mutations in BRAF account for only approximately 5–15 %
of CRC cases [29], although their presence has been strongly
associated with poorer outcomes [30, 31]. From our screen of
15 human CRC lines it was found that the two most sensitive
to ganetespib exposure (RKO and LS-411 N) harbor activat-
ing BRAFV600E mutations. We have recently reported similar
potent activity for ganetespib in melanoma lines that show
acute dependence on mutant BRAFV600E [22]. For the CRC
patient who achieved a partial response in the initial Phase I
evaluation of ganetespib, no tumor tissue was available for
mutational analysis [21], and thus the underlying molecular
phenotype that dictated a high sensitivity to single-agent
ganetespib therapy could not be determined. In a subsequent
Phase II study of ganetespib in heavily pre-treated metastatic
colorectal patients [NCT01111838] no objective responses
were observed, although 2/15 evaluable patients (both with
G12V-mutant KRAS tumors) achieved durable stable disease
[32]. In that trial, all tumors were wild type for BRAF expres-
sion. Overall, while it remains to be determined whether
mutated BRAF represents an actionable target for HSP90
inhibitor therapy in CRC, our findings suggest that the full
potential of ganetespib is likely to be realized as part of novel
combinatorial approaches in this disease.
As part of the characterization of the prototypical
ansamycin family of HSP90 inhibitors, including
geldanamycin and its derivatives 17-allylamino-17-
d eme t h oxyg e l d a n amyc i n ( 1 7 -AAG) , a n d 17 -
dimethylaminoethylamino-17-demethoxygeldanamycin (17-
DMAG), it was discovered that these compounds could sen-
sitize a variety of tumor cell lines to the cytotoxic effects of IR
[33–36]. Similar activity has been seen with second-
generation HSP90 inhibitors [37–39], suggesting that targeted
HSP90 blockade represents a conserved and potentially at-
tractive strategy for enhancing cancer cell radiosensitivity.
Consistent with such reports, ganetespib acted as a
radiosensitizer to potentiate the effects of low dose IR in the
HCT 116 model. At the molecular level, it was found that
combined HSP90 inhibition and radiation impacted several
overlapping pathways that led to cell cycle dysregulation,
diminished DNA repair capacity and enhanced apoptosis. In
response to DNA damage, cells typically activate ataxia
telangiectasia-mutated (ATM)-CHK2 and/or ATM and Rad3
related (ATR)-CHK1 signaling pathways to arrest the cell
cycle and initiate DNA repair [40]. CHK1 plays an important
role in the activation and maintenance of the G2/M checkpoint
and, importantly, is an established HSP90 client. Accordingly,
ganetespib exposure alone was sufficient to destabilize CHK1
expression in HCT 116 cells and this effect was augmented
when cells were exposed to combined ganetespib-IR treat-
ment. These data suggested that the integrity of any radiation-
induced G2/M checkpoint was markedly compromised with
concurrent ganetespib treatment. CHK2 becomes activated in
response to double-strand DNA breaks (including those aris-
ing as a direct result of IR) and propagates such damage
signals through downstream targets involved in cell cycle
progression and apoptosis [40]. In this regard, analysis of
CHK2 regulation revealed that the induction of activated
CHK2 protein levels was potentiated by radiation exposure,
even using a largely ineffective dose (2 Gy)—reflecting the
higher degree of DNA double-strand breakage resulting from
combination treatment. This was linked to an impaired DNA
repair capability due to the ganetespib-driven loss of RAD51,
a critical protein for the homologous recombination pathway
of DNA double-strand break repair. Indeed, when HCT 116
cells were co-treated with ganetespib, damage repair mecha-
nisms appeared to be inhibited following irradiation as evi-
denced by robust increases in phosphorylated histone H2AX
expression. It is reasonable to suggest therefore that the
genotoxic stress induced by the interplay of these cellular
responses was sufficient to account for the increased cell death
observed when the two modalities of HSP90 blockade and
irradiation were combined.
An important finding of this study, and one with clear
clinical relevance, was the capacity of ganetespib to signifi-
cantly improve the efficacy of fluoropyrimidine therapy in
HCT 116 xenografts. For five decades now, 5-FU has played
an indispensable role in CRC treatment, both in the curative
and palliative settings [3]. 5-FU acts as an antimetabolite to
disrupt DNA and RNA synthesis and repair, ultimately lead-
ing to cancer cell death. It is the backbone of the FOLFOX (5-
FU/LV plus oxaliplatin) and FOLFIRI (5-FU/LV plus
irinotecan) combination therapies that represent the standard
first line cytotoxic regimens for metastatic CRC patients. The
two regimens are equivalent in terms of efficacy, with selec-
tion of one over the other largely dependent on different
toxicity profiles and patient performance status [41]. Due to
a short half-life and significant variations in bioavailability, 5-
FU requires intravenous infusion (bolus and/or continuous)
and the first oral prodrug formulation, capecitabine, received
FDA approval in 2005 for adjuvant monotherapy use [42].
HCT 116 cells exhibited a high tolerance to 5-FU treatment
in vitro, believed to be linked to their DNA mismatch-repair
deficient phenotype [43]. In vivo, capecitabine administered
on a clinically relevant dosing schedule suppressed HCT 116
xenograft growth by over half. Single-agent ganetespib treat-
ment showed a similar, modest degree of tumor growth inhi-
bition in xenografted HCT 116 tumors, comparable to what
has previously been reported for 17-DMAG [44]. However,
when the two drugs were combined, we observed a significant
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improvement in antitumor efficacy resulting in greater than
50 % tumor regression. A synergistic interaction between 5-
FU and the HSP90 inhibitor NVP-AUY922 has previously
been reported in bladder cancer cell lines; no correlative
translation into in vivo efficacy was shown in that study
[45]. Thus, to our knowledge, this is the first demonstration
of combinatorial benefit between a small molecule HSP90
inhibitor and the fluoropyrimidine in CRC-derived tumors.
Further, our data showed that not only did the addition of
ganetespib to 5-FU-based therapy potentiate the activity of
the cytotoxic agent, but that targeted HSP90 inhibition could
overcome the intrinsic 5-FU resistant phenotype of HCT
116 cells.
The most dramatic recent clinical advances for patients
with metastatic CRC have resulted from the integration of
molecularly targeted agents, such as the anti-VEGF antibody
bevacizumab and the EGFR antagonists cetuximab and
panitumumab, into existing therapies [26]. An important les-
son gleaned from the development of those new therapeutic
strategies was that each of the biologics displayed minimal
clinical activity as single agents and their full benefit was only
realized when they were combined with standard treatment
regimens [3]. It is reasonable to suggest that this profile is
likely to be similar for the future application of selective
HSP90 inhibitors in CRC. Importantly, just as KRAS muta-
tions emerged as negative molecular predictors of response to
EGFR-targeted agents in this disease [46], the identification of
predictive biomarkers that identify those individuals most
likely to receive therapeutic benefit from HSP90 blockade
remains an ongoing clinical consideration. The findings pre-
sented here suggest a compelling rationale for exploiting the
chemosensitizing activity and capacity to overcome
fluoropyrimidine resistance displayed by ganetespib. In light
of these considerations, further investigation into the potential
benefits of ganetespib as an adjunct to 5-FU-based therapy is
warranted and a Phase I trial evaluating ganetespib in combi-
nation with capecitabine and radiation in rectal cancer
[NCT01554969] has recently been initiated.
In summary, we have shown that ganetespib exhibits
robust cytotoxic activity in preclinical models of CRC due
to coordinate effects on multiple cellular signaling pathways,
DNA repair mechanisms, and cell cycle progression. The
data presented here suggest that ganetespib may offer con-
siderable promise for therapeutic intervention in CRC, par-
ticularly as part of novel combinatorial strategies with
existing standard of care regimens. Moreover these findings
establish a novel framework for the design of future
ganetespib-based approaches to improve patient outcomes
in this disease.
Acknowledgments We wish to thank Tim Korbut and for his expertise
and assistance with the animal experiments and to all members of the
Cancer Biology Group.
Ethical standards We declare that all experiments were performed in
compliance with all laws of the United States of America.
Conflict of interest All authors are current employees of Synta
Pharmaceuticals Corp.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA
Cancer J Clin 63:11–30
2. Cummings LC, Cooper GS (2011) Colorectal cancer screening:
update for 2011. Semin Oncol 38:483–489
3. Aparo S, Goel S (2012) Evolvement of the treatment paradigm for
metastatic colon cancer. From chemotherapy to targeted therapy. Crit
Rev Oncol Hematol 83:47–58
4. TaipaleM, Jarosz DF, Lindquist S (2010) HSP90 at the hub of protein
homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol
11:515–528
5. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of
cancer. Nat Rev Cancer 5:761–772
6. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the
dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537–549
7. Xu W, Neckers L (2007) Targeting the molecular chaperone heat
shock protein 90 provides a multifaceted effect on diverse cell sig-
naling pathways of cancer cells. Clin Cancer Res 13:1625–1629
8. Banerji U (2009) Heat shock protein 90 as a drug target: some like it
hot. Clin Cancer Res 15:9–14
9. Taldone T, Gozman A, Maharaj R, Chiosis G (2008) Targeting
Hsp90: small-molecule inhibitors and their clinical development.
Curr Opin Pharmacol 8:370–374
10. Li Y, Zhang T, Schwartz SJ, Sun D (2009) New developments in
Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical
perspective and more potential. Drug Resist Updat 12:17–27
11. YingW, Du Z, Sun L, Foley KP, Proia DA et al (2012) Ganetespib, a
unique triazolone-containing Hsp90 inhibitor, exhibits potent antitu-
mor activity and a superior safety profile for cancer therapy. Mol
Cancer Ther 11:475–484
12. Zhou D, Liu Y, Ye J, Ying W, Ogawa LS et al (2013) A rat
retinal damage model predicts for potential clinical visual
disturbances induced by Hsp90 inhibitors. Toxicol Appl
Pharmacol 273:401–409
13. Proia DA, Sang J, He S, Smith DL, Sequeira M et al (2012)
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes
in non-small cell lung cancer models. Investig New Drugs 30:2201–
2209
14. Acquaviva J, Smith DL, Sang J, Friedland JC, He S et al (2012)
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90
inhibitor ganetespib. Mol Cancer Ther 11:2633–2643
15. Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ et al (2012)
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has
potent antitumor activity in in vitro and in vivo models of non-small
cell lung cancer. Clin Cancer Res 18:4973–4985
16. Friedland JC, Smith DL, Sang J, Acquaviva J, He S et al (2013)
Targeted inhibition of Hsp90 by ganetespib is effective across a broad
spectrum of breast cancer subtypes. Investig New Drugs 32:14–24
Invest New Drugs (2014) 32:577–586 585
17. Proia DA, Zhang C, Sequeira M, Jimenez JP, He S et al (2014)
Preclinical activity profile and therapeutic efficacy of the HSP90
inhibitor ganetespib in triple-negative breast cancer. Clin Cancer
Res 20:413–424
18. He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J et al (2013)
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer
cells irrespective of androgen receptor status or variant receptor
expression. Int J Oncol 42:35–43
19. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic Vet al
(2013) A multicenter Phase II study of ganetespib monotherpay in
patients with genotypically-defined advanced non-small cell lung
cancer. Clin Cancer Res 19:3068–3077
20. Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M et al
(2013) Targeted inhibition of the molecular chaperone Hsp90 over-
comes ALK inhibitor resistance in non-small cell lung cancer. Cancer
Discov 3:430–443
21. Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F et al
(2013) A first in human, safety, pharmacokinetics, and clinical activ-
ity phase I study of once weekly administration of the Hsp90 inhibitor
ganetespib (STA-9090) in patients with solid malignancies. BMC
Cancer 13:152
22. Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M et al
(2014) Overcoming acquired BRAF inhibitor resistance inmelanoma
via targeted inhibition of Hsp90 with ganetespib. Mol Cancer Ther
13:353–363
23. Tse AN, Carvajal R, Schwartz GK (2007) Targeting checkpoint
kinase 1 in cancer therapeutics. Clin Cancer Res 13:1955–1960
24. Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibi-
tors: are we there yet? Clin Cancer Res 18:64–76
25. Kline CL, El-Deiry WS (2013) Personalizing colon cancer therapeu-
tics: targeting old and new mechanisms of action. Pharmaceuticals
(Basel) 6:988–1038
26. El Zouhairi M, Charabaty A, Pishvaian MJ (2011) Molecularly
targeted therapy for metastatic colon cancer: proven treatments and
promising new agents. Gastrointest Cancer Res 4:15–21
27. Nagaraju GP, Park W, Wen J, Mahaseth H, Landry J et al (2013)
Antiangiogenic effects of ganetespib in colorectal cancer mediated
through inhibition of HIF-1alpha and STAT-3. Angiogenesis 16:903–
917
28. da Rocha DS, Friedlos F, Light Y, Springer C, Workman P et al
(2005) Activated B-RAF is an Hsp90 client protein that is targeted by
the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
Cancer Res 65:10686–10691
29. Pakneshan S, Salajegheh A, Smith RA, Lam AK (2013)
Clinicopathological relevance of BRAF mutations in human cancer.
Pathology 45:346–356
30. Thiel A, Ristimaki A (2013) Toward a molecular classification of
colorectal cancer: the role of BRAF. Front Oncol 3:281
31. Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A et al
(2013) BRAFV600E mutation analysis in patients with metastatic
colorectal cancer (mCRC) in daily clinical practice: correlations with
clinical characteristics, and its impact on Patients’ outcome. PLoS
One 8:e84604
32. Cercek A, Shia J, Gollub M, Raasch PJ, Hollywood E et al (2012)
Phase II study of ganetespib, an hsp-90 inhibitor, in patients with
refractory metastatic colorectal cancer. J Clin Oncol 30:467
33. Machida H, Matsumoto Y, Shirai M, Kubota N (2003)
Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells
to radiation. Int J Radiat Biol 79:973–980
34. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A et al
( 2 0 0 3 ) G e l d a n a m y c i n a n d 1 7 - a l l y l a m i n o - 1 7 -
demethoxygeldanamycin potentiate the in vitro and in vivo radiation
response of cervical tumor cells via the heat shock protein 90-
mediated intracellular signaling and cytotoxicity. Cancer Res 63:
8984–8995
35. Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ
(2003) Enhanced cell killing induced by the combination of radiation
and the heat shock protein 90 inhibitor 17-allylamino-17-
demethoxyge ldanamyc in : a mul t i t a rge t approach to
radiosensitization. Clin Cancer Res 9:3749–3755
36. Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM et al
(2008) HSP90 inhibitor, DMAG, synergizes with radiation of lung
cancer cells by interfering with base excision and ATM-mediated
DNA repair. Mol Cancer Ther 7:1985–1992
37. Yin X, Zhang H, Lundgren K, Wilson L, Burrows F et al
(2010) BIIB021, a novel Hsp90 inhibitor, sensitizes head and
neck squamous cell carcinoma to radiotherapy. Int J Cancer
126:1216–1225
38. Gandhi N, Wild AT, Chettiar ST, Aziz K, Kato Y et al (2013) Novel
Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
Cancer Biol Ther 14:347–356
39. Segawa T, Fujii Y, Tanaka A, Bando S, Okayasu R et al (2014)
Radiosensitization of human lung cancer cells by the novel purine-
scaffold Hsp90 inhibitor, PU-H71. Int J Mol Med 33:559–564
40. Bartek J, Lukas J (2003) Chk1 and Chk2 kinases in checkpoint
control and cancer. Cancer Cell 3:421–429
41. Catenacci DV, Kozloff M, Kindler HL, Polite B (2011) Personalized
colon cancer care in 2010. Semin Oncol 38:284–308
42. Hirsch BR, Zafar SY (2011) Capecitabine in the management of
colorectal cancer. Cancer Manag Res 3:79–89
43. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA
(2001) Role of the hMLH1 DNA mismatch repair protein in
fluoropyrimidine-mediated cell death and cell cycle responses.
Cancer Res 61:5193–5201
44. Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S et al
(2007) Blocking heat shock protein-90 inhibits the invasive proper-
ties and hepatic growth of human colon cancer cells and improves the
efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
Mol Cancer Ther 6:2868–2878
45. Lee KH, Lee JH, Han SW, Im SA, Kim TY et al (2011)
Antitumor activity of NVP-AUY922, a novel heat shock pro-
tein 90 inhibitor, in human gastric cancer cells is mediated
through proteasomal degradation of client proteins. Cancer
Sci 102:1388–1395
46. Grothey A, Lenz HJ (2012) Explaining the unexplainable: EGFR
antibodies in colorectal cancer. J Clin Oncol 30:1735–1737
586 Invest New Drugs (2014) 32:577–586
